- First mover for
Celltrion has proven its competitive edge with explosive growth in the oncology biosimilar market.
Celltrion received EMA approval for Truxima, a blood cancer biosimilar, in 2017. Truxima took up 32% of the European market in just a year. Herzuma, a biosimilar for breast cancer and gastric cancer, recorded a 10% market share in the European market only six months after its release.
Truxima’s Market Share Growth
- The first Rituximab
in the United States
In 2018, Celltrion obtained United States FDA approval for Truxima, a Rituximab biosimilar. Now the company is nearing its entry into the world’s largest Rituximab market in the world with a total worth of approximately 4.2 billion dollars. We aim to actively expand our presence in the market with our exclusive biosimilar product as competitors discontinue their trials and abandon their plans to access the American market, and secure a dominant position as we did in the European market.
Percentage of Rituximab Sales by Country
Annual Global Sales USD 6.7 billion
Rituximab Price in the United States of America and EuropeUnited States: 500mg WAC / Other countries: list price
Celltrion has secured a total of seven pipelines for oncology biosimilars. In particular, we are currently in Phase 3 clinical trials for CT-P16, an Avastin biosimilar for non-small cell lung cancer and colon cancer with a 6.7 billion dollar global market.